shares in virbac fell tuesday after the company lowered its expectations for fiscal 2023 due to an overall market growth slowdown and production capacity constraints for vaccines at 0827 gmt shares in virbac were down 830 at eur24850 the french animalhealth pharmaceutical company now expects revenue growth between 0 and 4 at constant rates and scope instead of the initial forecast in a range of 4 to 6 the ratio of adjusted earnings before interest and taxesdefined as the ratio of current operating profit before amortization of assets resulting from acquisitions to revenueis seen between 12 and 13 at constant rate changes the company had previously forecast an adjusted ebit ratio between 13 and 14 virbac also said it experienced a cyberattack on june 19 that affected its performance but hasnt yet been able to accurately measure the implications despite the changes in the forecast for the current year the company maintained its expectations for 2030